A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Condition(s):HER2 Positive Breast CancerLast Updated:March 12, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):HER2 Positive Breast CancerLast Updated:March 12, 2024Recruiting
Condition(s):HER2-positive Metastatic Breast Cancer; Central Nervous System MetastasesLast Updated:June 13, 2023Active, not recruiting
Condition(s):HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerLast Updated:June 14, 2018Completed
Condition(s):Advanced HER2+Breast CancerLast Updated:February 28, 2024Active, not recruiting
Condition(s):Breast CarcinomaLast Updated:July 12, 2023Active, not recruiting
Condition(s):Breast CancerLast Updated:August 25, 2015Completed
Condition(s):Non-small Cell Lung CancerLast Updated:July 7, 2015Completed
Condition(s):Breast CancerLast Updated:February 20, 2024Recruiting
Condition(s):Pancreatic CancerLast Updated:March 3, 2017Terminated
Condition(s):HER2-positive Breast CancerLast Updated:July 14, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.